All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2025-02-13.
From the record
Ovid Therapeutics Inc.'s filings since 2017 show 1 warning event: a notice about its exchange listing (8-K item 3.01, the latest 2025-02-13) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-56.8% a year over 5 filed years; profitable in 1 of 5.
From the record
Ovid Therapeutics Inc.'s 5 filed years say what it did: revenue went from $208 million in fiscal 2021 to $7 million in fiscal 2025, down 56.8% a year; it rose in 2 of 4 years; the deepest fall was 100% from fiscal 2021 to fiscal 2023; net income was positive in 1 of 5 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 5.8/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Ovid Therapeutics Inc.'s shareholder treatment is put at 5.8 of 10 with a confidence of 20 of 100, because fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income, so the desk assumes the typical reading of its industry family, the median of 295 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -13%: lost 13¢ per shareholder dollar. Leverage 13%: owes 13¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Ovid Therapeutics Inc. lost about 13 cents for every dollar of shareholders' money. Leverage: it owed about 13 cents per dollar of assets (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 45% of 315 in its family; net margin -240.1%.
From the record
Ovid Therapeutics Inc.'s standing among 315 graded names in its industry family: revenue of $7 million in fiscal 2025 ranks in the bottom 37% by size; a net margin of -240.1% ranks in the bottom 44%; revenue growth of 69% a year over the last 3 filed years ranks in the top 18% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 29% of 315 in its family for leadership; chief executive since 2026.
From the record
Ovid Therapeutics Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Alexander, Margaret A. (President and CEO, as filed), filing under that title since 2026-01-05, 10 months (bottom 13% of its family); the 10 officers and directors filing in the last fifteen months have been on the record a median of 5.6 years (bottom 49%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 10 people in charge now (bottom 26%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 41% of 273 in its family for room to expand.
From the record
Ovid Therapeutics Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $13 million against no long-term debt tagged leaves 8.7% of its assets as net cash, bottom 23% of its family; cash from operations less capital spending is -528.6% of revenue (bottom 33%); research spending of 352.8% of revenue (top 35%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 19% of 306 in its family for growth drivers.
From the record
Ovid Therapeutics Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 69% a year over the last three filed years against -56.8% over all 5, speeding up (top 4% of its family); the newest year grew 1183.5% (top 3%); research spending grew 1.3% a year (bottom 50%) (its annual reports). Ovid Therapeutics Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 13% of 233 in its family for expectations against reality.
From the record
Ovid Therapeutics Inc.'s newest year against its own record: revenue of $7 million in fiscal 2025 came in 1987% above the $347 thousand its prior three years' pace pointed to (top 4% of its family); net income of $17 million against a prior three-year average of $44 million (top 27%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 8%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made